For many dermatology practices, skin biopsies and lesion excisions represent a large share of procedural volume and revenue. Yet these are also some of the most frequently under‑coded, miscoded, and denied services in the specialty. Small errors in lesion size documentation, biopsy vs excision selection, or modifier usage can quietly drain tens of thousands of dollars from annual collections, trigger audits, and frustrate providers who feel they are “doing the work but not seeing the revenue.”
This problem is more urgent now than it was a few years ago. Payers are using increasingly sophisticated analytics to flag patterns in dermatology coding, particularly around skin procedures and minor surgeries. At the same time, staffing churn in billing and coding teams has increased, which often means that nuanced dermatology rules get lost in generic training.
This article is designed for practice owners, group practice leaders, hospital RCM executives, and billing company owners who want to:
- Improve first pass payment rates for dermatology procedures
- Reduce preventable denials tied to coding and documentation
- Standardize provider and coder behavior around biopsies and excisions
- Measure the impact of better dermatology coding on cash flow
We will not rehash basic CPT definitions. Instead, we will focus on how to operationalize accurate coding for biopsies and excisions inside a real revenue cycle, and how to build guardrails that protect your dermatology revenue long term.
1. Clarifying Biopsy vs Excision: A Decision Framework for Front‑Line Coders
The single most important decision in dermatology skin procedure coding is whether a service is billed as a biopsy or an excision. This is not simply a matter of technique (shave vs punch vs elliptical) but of intent and extent of removal. Payers and auditors look closely at this distinction, especially when patterns suggest upcoding or inconsistent use of pathology results.
A practical decision framework
Implement a simple, standardized decision tree that every coder and auditor uses when reviewing skin procedure notes:
- Step 1: What was the clinical intent documented?
Is the note explicit that the provider removed a sample “for diagnostic purposes” to determine the nature of the lesion, or does it state that the lesion was “completely removed” for therapeutic reasons, such as symptomatic relief or oncologic management? - Step 2: Was the entire gross lesion removed?
Even if a “shave” or “punch” technique was used, if the provider documents complete removal of the visible lesion with margins, this typically aligns with excision coding rather than biopsy. - Step 3: Is there any language that conflicts with the billed code?
Phrases like “partial sample” or “representative tissue” contradict an excision code. Phrases like “lesion fully removed with margins” raise questions if a biopsy code is used.
Use this decision framework as part of coder training and internal audits. Do not rely on provider memory or “how we have always coded it.” The record must stand on its own.
Operational and revenue implications
Misclassification of biopsies and excisions has direct financial consequences:
- Undercoding (billing biopsy where excision is appropriate) reduces reimbursement on every case. Across a busy dermatology program, a small per‑case variance multiplied by hundreds of claims per month becomes a substantial revenue leak.
- Overcoding (billing excision where documentation supports only biopsy) increases audit risk, repayment exposure, and can lead to prepayment medical review.
What leaders should do next:
- Build a one‑page biopsy vs excision decision aid into your coding manual or EHR coding resources.
- Include at least 10 dermatology cases in every new coder’s competency check, focusing on this distinction.
- Audit 10 to 20 recent skin procedures per provider to verify whether intent and extent of removal match the codes used.
2. Getting Excised Diameter and Location Right: Turning Documentation into Reimbursable Detail
Excision codes for benign and malignant lesions depend heavily on two documentation elements: anatomical location and excised diameter. Both are often incomplete or ambiguous in dermatology notes, which forces coders to guess or default to lower‑paying codes. Payers know this and target these fields when looking for under‑ or over‑billing.
Defining excised diameter in operational terms
Excised diameter is not simply the size of the lesion. It is the sum of:
- The largest clinical diameter of the lesion, plus
- Two times the smallest margin of normal tissue taken around that lesion.
For example, if a lesion is 0.8 cm and the provider documents taking 0.2 cm margin on all sides, the excised diameter is 1.2 cm (0.8 + 0.2 + 0.2). If a coder picks a code based only on 0.8 cm, the practice is underpaid.
Building better documentation habits
Rather than occasional reminders, institutionalize the required fields for every dermatology excision note:
- Exact anatomical site (for example, “left lateral cheek near zygomatic arch,” not simply “face”).
- Lesion size before removal, in centimeters.
- Margins taken, ideally documented as numeric values or descriptive phrases like “1 mm circumferential margin.”
- Final total excised diameter, or enough detail so coders can calculate it unambiguously.
Configure EHR smart phrases or procedure templates so that these fields appear as prompts every time a provider documents a lesion excision. The goal is that missing lesion size or margins become the rare exception rather than the norm.
KPIs to monitor
- Percentage of excision claims with fully documented lesion size and margins
Target at least 95 percent. Anything lower suggests systemic documentation gaps. - Average excision payment per CPT family (for example, trunk/extremities, face/ears)
Track pre‑ and post‑documentation improvement. A measurable bump after template changes is a strong sign that documentation and coding are now aligned.
Without accurate documentation of size and location, you are effectively negotiating against yourself in every payer contract, because you cannot bill at the level of work actually performed.
3. Avoiding the Top Denial Triggers: Documentation, Modifiers, and Unbundling
Most dermatology claim denials around biopsies and excisions fall into a handful of recurring categories. Addressing these proactively is far more efficient than chasing appeals months later. Below are the primary denial drivers and how to engineer them out of your workflow.
Documentation that does not demonstrate medical necessity
Payers are tightening coverage around lesions that appear benign, cosmetic removals, and “rule out” procedures lacking clear clinical concern. Common problems include:
- Notes that simply say “mole removal” without describing suspicious features, patient symptoms, or change over time.
- Diagnosis codes that suggest cosmetic conditions rather than medical indications.
Prevention steps:
- Standardize lesion documentation to include characteristics such as asymmetry, border irregularity, color variation, diameter changes, bleeding, pruritus, or failure to heal.
- Align diagnosis selection with these findings, especially for uncertain or suspicious lesions (for example, neoplasm of uncertain behavior when clinically appropriate).
- Educate providers that payers review both the CPT and ICD combination and that “it looked odd” is not defensible without objective description.
Modifier misuse around same‑day E/M and procedures
Two modifiers generate consistent problems in dermatology:
- Modifier 25 for significant, separately identifiable E/M service on the same day as a minor procedure.
- Modifier 59 or X modifiers for distinct procedural services when multiple procedures occur in one session.
Overuse of modifier 25, especially when the E/M document duplicates procedure decision‑making, is a known audit target. Misapplied modifier 59 can lead to bundling edits and denials or, worse, accusations of unbundling.
Prevention steps:
- Define clear internal criteria for when modifier 25 is allowed. For example, new problem not related to the procedure and separate history, exam, and plan beyond the pre‑operative assessment.
- Use NCCI (National Correct Coding Initiative) edits as the baseline for when modifier 59 is appropriate, and build payer‑specific rules into your practice management or scrubber system.
- Review provider E/M documentation in random samples where modifier 25 was used to ensure the level of service is justified.
Unbundling services included in the primary code
Many skin biopsy and excision codes include components such as local anesthesia and simple wound closure. Separate billing for these bundled services will trigger denials and put your coding profile at risk.
Prevention steps:
- Train coders and billers on what is inherently included for each major CPT family in dermatology.
- Configure your scrubber to flag combinations like simple repair codes submitted with an excision code on the same site and date of service.
- Reserve additional closure codes for documented intermediate or complex repairs that truly exceed what is bundled.
By treating these denial triggers as design problems rather than isolated coder errors, you can architect a dermatology revenue cycle that naturally produces clean claims.
4. Aligning Pathology and Diagnosis Coding: Closing the Loop Between Clinician, Lab, and RCM
Biopsies and excisions are unique in that the final nature of the lesion is often not known at the time of the encounter. However, payers expect the billed diagnosis and the type of excision (benign vs malignant) to align with the final pathology report. Disconnects here can lead to denials, overpayments, and compliance risk.
Why pathology integration is critical
Consider the following operational scenarios:
- A lesion is documented as “suspicious” and a biopsy is performed. The claim is billed with a code for an uncertain neoplasm. Pathology later confirms melanoma. If the diagnosis and subsequent excision do not reflect this malignancy, future claims and risk adjustment may be inaccurate.
- An excision is billed as malignant based on provider suspicion, but pathology returns benign. If your process does not reconcile codes after final pathology, you risk overstating disease burden and billing at a higher level than supported.
Both situations expose the practice or health system to audit findings. Inconsistent linkage between pathology and diagnosis codes is easy for payers to detect at scale.
Building a closed‑loop workflow
Revenue cycle leaders should design a specific, repeatable process for pathology reconciliation:
- Step 1: Flag all skin biopsies and excisions that are pending pathology.
This can be handled via EHR work queues or simple tracking fields maintained by coding staff. - Step 2: Assign responsibility for updating diagnosis codes when pathology results arrive.
In some organizations this is the provider, in others a certified coder working from clearly defined rules. Choose one owner and make it explicit. - Step 3: Establish timing expectations.
For example, pathology reconciliation within seven calendar days of result finalization. This avoids a backlog that is never addressed. - Step 4: Define when claims must be corrected or adjusted.
For encounters already billed, set criteria for when an adjustment claim or corrected claim should be submitted, especially if benign vs malignant status changes.
Metrics to track
- Percentage of dermatology biopsy/excision encounters with diagnosis updated after pathology, when indicated.
- Number of audit findings or payer inquiries tied to benign vs malignant code inconsistencies.
Integrating pathology with RCM is not simply a clinical quality issue. It is a revenue integrity function that protects your organization from both underpayment and overpayment risk.
5. Standardizing Dermatology‑Specific Templates, Training, and Quality Review
Many practices and even large health systems rely on generic procedure templates and coder onboarding that are not tailored to dermatology. As a result, dermatology claims behave like outliers: higher denial rates, more add‑on documentation requests, and unpredictable reimbursement.
Key building blocks of a dermatology‑aware documentation toolkit
To bring dermatology into alignment with broader revenue cycle goals, create a dedicated toolkit that includes:
- Procedure note templates for biopsies and excisions
These should prompt for intent (diagnostic vs therapeutic), lesion size, margins, anatomical site, closure type, and medical necessity elements. - Diagnosis picklists aligned with payer expectations
Make it easy for providers to select appropriate ICD‑10 codes that reflect the clinical scenario rather than defaulting to vague or cosmetic codes. - Quick‑reference coding guides
Not full manuals, but one or two page references with the most common biopsy and excision codes, grouped by site and excised diameter, plus reminders on what is bundled.
Dermatology‑focused coder training and QA
Dermatology coding should be treated as a distinct competency area, not a minor add‑on to general surgery or outpatient coding. At minimum, your coding and QA program should include:
- A dedicated training module on dermatology biopsies and excisions for new coders.
- Quarterly audits of a statistically meaningful sample of dermatology encounters, with feedback loops to both coders and providers.
- Side‑by‑side reviews between senior coders and clinicians to resolve ambiguous documentation patterns and refine templates.
From a leadership standpoint, standardization has measurable benefits. It reduces coder variation, shortens time‑to‑productivity for new staff, and allows you to compare provider performance on apples‑to‑apples terms.
6. Measuring the Financial Impact: KPIs and Dashboards for Dermatology Revenue
Without measurement, any dermatology coding initiative will lose momentum. Executives and practice owners need a concise set of indicators that tie biopsy and excision accuracy to tangible financial and operational outcomes.
Core dermatology revenue and quality KPIs
- First pass acceptance rate for dermatology claims
Overall, and specifically for biopsy and excision CPT groups. Target 90 percent or better. - Denial rate for dermatology procedures by reason code
Break out medical necessity, bundling, modifier, and diagnosis mismatch categories. Any category over 5 percent warrants a targeted intervention. - Average reimbursement per common excision and biopsy codes
Benchmark internally over time. Sudden drops may indicate payer policy shifts or internal undercoding trends. - Days in A/R for dermatology procedures
If dermatology encounters have significantly longer A/R than other specialties, coding and documentation issues are a likely contributor.
How to use these metrics in governance
Establish a regular RCM review cadence, such as monthly or quarterly, that includes:
- A brief dermatology segment presented by coding leadership or your billing partner.
- Trend charts comparing pre‑intervention and post‑intervention performance for biopsies and excisions.
- Specific action items, such as revising templates, conducting focused provider education, or updating edits and scrubber logic.
The goal is not to drown stakeholders in data, but to clearly show that improvements in dermatology coding translate to predictable improvements in cash flow, fewer denials, and less administrative friction with payers.
7. Deciding When to Partner: When Internal Teams Need External Dermatology RCM Expertise
Even well‑run organizations may struggle to sustain dermatology‑specific expertise in house. Turnover among coders, expanding service lines, and evolving payer rules can outpace internal training capacity. At that point, partnering with a specialist RCM vendor can be the practical choice.
Signals that you may need external support
- Dermatology denial rates remain high despite internal education efforts.
- Audit findings or payer letters specifically cite biopsy vs excision issues or documentation insufficiency.
- Coding teams report low confidence in dermatology cases compared with other surgical specialties.
- Dermatology accounts for a disproportionate share of your rework and appeals volume.
A qualified partner brings seasoned dermatology coders, established audit workflows, and tested documentation templates. They can also benchmark your performance against a broader client base and identify where payer behavior is shifting before it hits your bottom line.
If your practice, group, or health system is at that inflection point, it may be time to explore a structured engagement. You can connect with our team to discuss how external dermatology RCM support could stabilize and grow your revenue from biopsies and excisions.
Protecting Dermatology Revenue with Deliberate Coding Design
Accurate dermatology coding for skin biopsies and excisions is not a matter of memorizing CPT tables. It requires clear clinical intent, disciplined documentation of size and location, thoughtful use of modifiers, tight integration with pathology, and specialty‑aware training and QA. When these elements are designed into your revenue cycle, denials fall, audit risk decreases, and the financial contribution of dermatology becomes more predictable.
For independent practices, group practices, hospitals, and billing companies, the business case is straightforward. Even modest improvements in biopsy and excision coding accuracy generate a meaningful return on investment, both in recovered revenue and in reduced back‑office workload.
If you are ready to translate these concepts into a concrete plan tailored to your organization, you can reach out to our specialists for a focused discussion on your dermatology revenue strategy.
References
Centers for Medicare & Medicaid Services. (n.d.). National Correct Coding Initiative (NCCI). Retrieved from https://www.cms.gov/national-correct-coding-initiative-ncci
Medicare Learning Network. (2020). Evaluation and Management Services Guide. Centers for Medicare & Medicaid Services. Retrieved from https://www.cms.gov/files/document/mln006764-evaluation-management-services.pdf
